16 April 2026
EIB, EC and IFC back Biovac to build Africa’s first end-to-end vaccine manufacturing plant
€75M quasi‑equity and $20M senior loan finance a South African end‑to‑end multi‑vaccine plant (2028) to produce cholera, polio, pneumonia and meningitis vaccines (30–40M doses/yr); 340 skilled, 7,000 indirect jobs.